Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott Hall

Showing results (131-140 of 161) with videos related to

Pageof 17
Sort By:
Psychopharmacology|February 12, 2013
Impaired cliff avoidance reaction in dopamine transporter knockout miceMotoyasu Yamashita, Yasufumi Sakakibara, F Scott Hall, et al.
Behavioural Pharmacology|February 22, 2014
Agmatine attenuates methamphetamine-induced hyperlocomotion and stereotyped behavior in miceNobue Kitanaka, Junichi Kitanaka, F Scott Hall, et al.
Brain Research Bulletin|June 3, 2025
Sodium-glucose cotransporter-2 inhibitor, dapagliflozin, reverses depressive-like behavior in a mouse model of post-traumatic stress disorderHaneen Amawi, Tayma Makhlouf, Alaa M Hammad, et al.
Behavioural Pharmacology|September 29, 2025
Pretreatment with LY2090314, a potent glycogen synthase kinase-3 inhibitor, suppresses methamphetamine-induced stereotyped behavior but not hyperlocomotion in miceKentaro Matsuda, Nobue Kitanaka, Frank Scott Hall, et al.
Psychopharmacology|March 23, 2007
Methamphetamine-induced locomotor activity and sensitization in dopamine transporter and vesicular monoamine transporter 2 double mutant miceSetsu Fukushima, Haowei Shen, Harumi Hata, et al.
Biochemical and Biophysical Research Communications|February 16, 2013
Exclusive expression of VMAT2 in noradrenergic neurons increases viability of homozygous VMAT2 knockout miceArihisa Ohara, Yoshiyuki Kasahara, Hideko Yamamoto, et al.
Journal of Pharmacological Sciences|February 24, 2023
Role for μ-opioid receptor in antidepressant effects of δ-opioid receptor agonist KNT-127Yuki Moriya, Yoshiyuki Kasahara, Masafumi Shimada, et al.
Metabolic Brain Disease|May 20, 2025
Rhoifolin as a potential anxiolytic drug for the effects of nicotine withdrawal: beneficial effects on behavior, neuroinflammation, and oxidative stressAlaa M Hammad, Suhair Sunoqrot, Thanaa Al-Zuhd, et al.
Brain Research|January 24, 2012
Pretreatment with nomifensine or nomifensine analogue 4-phenyl-1,2,3,4-tetrahydroisoquinoline augments methamphetamine-induced stereotypical behavior in miceJunichi Kitanaka, Nobue Kitanaka, F Scott Hall, et al.
Journal of Neurodevelopmental Disorders|October 30, 2009
A solution to limitations of cognitive testing in children with intellectual disabilities: the case of fragile X syndromeDavid Hessl, Danh V Nguyen, Cherie Green, et al.
Pageof 17

Showing results (131-140 of 161) with videos related to

Sort By:
Pageof 17
Psychopharmacology|February 12, 2013
Impaired cliff avoidance reaction in dopamine transporter knockout miceMotoyasu Yamashita, Yasufumi Sakakibara, F Scott Hall, et al.
Behavioural Pharmacology|February 22, 2014
Agmatine attenuates methamphetamine-induced hyperlocomotion and stereotyped behavior in miceNobue Kitanaka, Junichi Kitanaka, F Scott Hall, et al.
Brain Research Bulletin|June 3, 2025
Sodium-glucose cotransporter-2 inhibitor, dapagliflozin, reverses depressive-like behavior in a mouse model of post-traumatic stress disorderHaneen Amawi, Tayma Makhlouf, Alaa M Hammad, et al.
Behavioural Pharmacology|September 29, 2025
Pretreatment with LY2090314, a potent glycogen synthase kinase-3 inhibitor, suppresses methamphetamine-induced stereotyped behavior but not hyperlocomotion in miceKentaro Matsuda, Nobue Kitanaka, Frank Scott Hall, et al.
Psychopharmacology|March 23, 2007
Methamphetamine-induced locomotor activity and sensitization in dopamine transporter and vesicular monoamine transporter 2 double mutant miceSetsu Fukushima, Haowei Shen, Harumi Hata, et al.
Biochemical and Biophysical Research Communications|February 16, 2013
Exclusive expression of VMAT2 in noradrenergic neurons increases viability of homozygous VMAT2 knockout miceArihisa Ohara, Yoshiyuki Kasahara, Hideko Yamamoto, et al.
Journal of Pharmacological Sciences|February 24, 2023
Role for μ-opioid receptor in antidepressant effects of δ-opioid receptor agonist KNT-127Yuki Moriya, Yoshiyuki Kasahara, Masafumi Shimada, et al.
Metabolic Brain Disease|May 20, 2025
Rhoifolin as a potential anxiolytic drug for the effects of nicotine withdrawal: beneficial effects on behavior, neuroinflammation, and oxidative stressAlaa M Hammad, Suhair Sunoqrot, Thanaa Al-Zuhd, et al.
Brain Research|January 24, 2012
Pretreatment with nomifensine or nomifensine analogue 4-phenyl-1,2,3,4-tetrahydroisoquinoline augments methamphetamine-induced stereotypical behavior in miceJunichi Kitanaka, Nobue Kitanaka, F Scott Hall, et al.
Journal of Neurodevelopmental Disorders|October 30, 2009
A solution to limitations of cognitive testing in children with intellectual disabilities: the case of fragile X syndromeDavid Hessl, Danh V Nguyen, Cherie Green, et al.
Pageof 17